肝移植前生物标志物组合预测术后死亡:LIFI指数的开发与内部验证
该前瞻性生物标志物分析纳入279例连续肝移植受者,发现移植前血浆fractalkine和MMP3是早期死亡独立预测因子,据此构建的Liver Immune Frailty Index(LIFI)将患者分为低、中、高风险,1年死亡率分别为1.9%、10.3%和63.6%,C统计量为0.83。
要点
- 移植前fractalkine和MMP3独立预测肝移植后1年死亡。
- LIFI高风险组1年死亡率63.6%,是低风险组的33.41倍。
- LIFI与术后感染、住院时间延长和生存率降低相关。
核心结论
- 移植前免疫功能障碍生物标志物组合LIFI可识别肝移植后早期死亡高风险患者,为术前客观评估提供工具。
研究设计与样本
- 前瞻性生物标志物分析,连续纳入279例成人肝移植受者,并设健康对照。
主要发现
- 移植前血浆BAFF、CCL1、eotaxin、fractalkine、IL-1β、sIL-6Rβ、MMP2和MMP3与肝移植后1年死亡率显著相关。
- 多因素Cox模型确定fractalkine和MMP3为独立预测因子。
- LIFI低、中、高风险组1年死亡率分别为1.9%、10.3%和63.6%。
- 与LIFI低风险组相比,中风险组1年死亡相对风险为5.43(95%CI 1.59-18.60;P<.001),高风险组为33.41(95%CI 11.48-97.25;P<.001)。
- LIFI区分度强,C统计量为0.83,并与术后感染、住院时间延长和生存率降低相关。
临床怎么用
- 可用于肝移植术前识别免疫功能障碍高风险患者,辅助移植候选资格决策。
- 可指导围术期管理,针对高风险患者加强监测和干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current pretransplant clinical scoring systems fail to accurately estimate post-liver transplant (LT) survival, making recipient selection challenging. Persistent immune dysfunction contributes to early LT recipient mortality but is not captured by existing models. OBJECTIVE: To identify plasma biomarkers of pretransplant immune dysfunction and to develop a biomarker-based pre-LT risk stratification tool to predict post-LT mortality. DESIGN, SETTING, AND PARTICIPANTS: Prospective biomarker analysis of consecutively enrolled adult LT recipients was conducted. Healthy controls were included for baseline comparison. Patients undergoing LT at Houston Methodist Hospital (October 1, 2013, to December 31, 2017) and Rutgers/University Hospital (January 1, 2019, to March 31, 2021) were enrolled under an institutional review board-approved protocol, and data were censored on March 31, 2023, and analyzed. Patients with cirrhosis older than 18 years undergoing deceased donor LT were included. Exclusion criteria were age greater than 70 years, cancer other than hepatocellular carcinoma, retransplant, status 1A, intraoperative mortality, multivisceral transplant (except liver-kidney), and sample availability. EXPOSURES: Plasma cytokine, chemokine, and immune exhaustion biomarkers were quantified using multiplex Luminex assays at the time of transplant. Clinical, demographic, and laboratory data were extracted from institutional databases. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality within 1 year of LT. Secondary outcomes included graft survival, infections, rejection, readmissions, and 24-month survival. RESULTS: A total of 779 adult LTs were performed between 2007 and 2017, with prospective biomarker analysis of 279 consecutively enrolled LT recipients between 2018 and 2022. Median (IQR) participant age was 56.7 (48.2-62.5) years, and 110 of 279 patients (39.4%) were female. Pre-LT plasma levels of B-cell activating factor, C-C motif chemokine ligand 1, eotaxin, fractalkine, interleukin 1β (IL-1β), sIL-6Rβ, metalloproteinase (MMP) 2, and MMP3 were significantly associated with 1-year post-LT mortality. Multivariable Cox proportional hazards modeling identified fractalkine and MMP3 as independent predictors of early post-LT mortality. These were used to develop the Liver Immune Frailty Index (LIFI), stratifying patients into low, moderate, and high risk. One-year mortality was 1.9%, 10.3%, and 63.6% for LIFI-low, -moderate, and -high, respectively. Relative risk of death within 1 year was 5.43 (95% CI, 1.59-18.60; P < .001) for LIFI-moderate and 33.41 (95% CI, 11.48-97.25; P < .001) for LIFI-high compared to LIFI-low. LIFI demonstrated strong discrimination (C statistic, 0.83) and was associated with post-LT infections, longer hospital stays, and reduced patient survival. CONCLUSIONS AND RELEVANCE: Per the results of this diagnostic/prognostic study, LIFI identifies LT candidates with severe immune dysfunction at high risk for early post-LT mortality, offering a preoperative, objective tool to refine transplant candidacy, guide perioperative management, and improve LT outcomes.
引用
- Panayotova GG, Simonishvili S, Jin L, et al. Development and Internal Validation of a Pretransplant Biomarker Panel for Mortality Prediction Following Liver Transplant. JAMA Surg. 2026. PMID: 41670973. doi:10.1001/jamasurg.2025.6539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。